BARR RECEIVES FDA APPROVAL FOR GENERIC XANAX
Barr Laboratories has it received final approval from the FDA for its application to manufacture and market a generic version of Pfizer's Xanax XR (alprazolam extended-release) Tablets, 0.5 mg, 1 mg, 2 mg and 3 mg. The company intends to launch its product immediately.
Xanax is indicated for the treatment of panic disorder, with or without agoraphobia. Barr's generic drug will compete in a market that had total annual sales of approximately $83 million for the twelve months ending May 2006, according to IMS sales data.